This is the communication: Learn About This Lat
Post# of 148190
(Total Views: 698)
Posted On: 02/19/2020 1:44:06 PM
This is the communication:
Learn About This Late Stage Biotechnology Company Developing Innovative Treatments: CytoDyn (OTCQB: CYDY)
Join the Investor Group Call on Thursday, February 20th at 4 PM ET
Dr. Nader Pourhassan, Director, President & CEO of CytoDyn Inc. (OTCQB: CYDY), a late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor, will host an investor group call Thursday, February 20, 2020 at 4 pm Eastern/1 pm Pacific.
To join the free call, which will not be archived, at 4 pm Eastern please dial 866-821-0302. There is no passcode. If you have any questions, please reach RedChip Specialist Craig Brelsford at (407) 571-0902, or reply to this email. Note to callers outside the United States: Please reach Craig Brelsford for the dial-in number for your country.
About CytoDyn Inc. (OTCQB: CYDY)
• CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor, in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients
• CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in the first quarter of 2020 for that indication
• Robust cancer and immunology pipeline; green light from FDA to initiate Phase 2 trial in colon cancer
• Experienced management team and Board of Directors; CEO has led the raise of approximately $90M of total $240M capital raised for CYDY over the last five years
More information:
cytodyn.com
cydyinfo.com
View Investor Deck
Disclosure
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC"
at www.sec.gov.
CytoDyn (CYDY) is a client of RedChip Companies, Inc. CYDY agreed to pay RedChip Companies, Inc., a $20,000 quarterly cash fee, beginning in February 2020, for RedChip investor awareness services.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.
Learn About This Late Stage Biotechnology Company Developing Innovative Treatments: CytoDyn (OTCQB: CYDY)
Join the Investor Group Call on Thursday, February 20th at 4 PM ET
Dr. Nader Pourhassan, Director, President & CEO of CytoDyn Inc. (OTCQB: CYDY), a late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor, will host an investor group call Thursday, February 20, 2020 at 4 pm Eastern/1 pm Pacific.
To join the free call, which will not be archived, at 4 pm Eastern please dial 866-821-0302. There is no passcode. If you have any questions, please reach RedChip Specialist Craig Brelsford at (407) 571-0902, or reply to this email. Note to callers outside the United States: Please reach Craig Brelsford for the dial-in number for your country.
About CytoDyn Inc. (OTCQB: CYDY)
• CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor, in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients
• CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in the first quarter of 2020 for that indication
• Robust cancer and immunology pipeline; green light from FDA to initiate Phase 2 trial in colon cancer
• Experienced management team and Board of Directors; CEO has led the raise of approximately $90M of total $240M capital raised for CYDY over the last five years
More information:
cytodyn.com
cydyinfo.com
View Investor Deck
Disclosure
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC"
at www.sec.gov. CytoDyn (CYDY) is a client of RedChip Companies, Inc. CYDY agreed to pay RedChip Companies, Inc., a $20,000 quarterly cash fee, beginning in February 2020, for RedChip investor awareness services.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼